A Phase 1 interventional study of Atorvastatin and Pravastatin in Rheumatoid Arthritis, sponsored by Gilead Sciences. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-14.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 16th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1, and was the 12th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Universita di Verona · Sites in Italy
Ages 18–65
R.Bos · Sites in Netherlands
Ages 18–101
Leiden University Medical Center · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 287 across the 17 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 8 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
12 studies in Arthritis, Rheumatoid by Gilead Sciences: none open now, 1 under way, none of them phase 3. Of 10 finished, 8 (80%) have results posted.
Among the 12 studies in Arthritis, Rheumatoid by Gilead Sciences, this one is the 8th largest by enrollment, is the only one that started in 2020, is one of 6 in phase 1, and was the 9th registered.
Gilead Sciences’s Arthritis, Rheumatoid studies by the year they started, since 2014.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 12 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of filgotinib on a mixed organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer resistance protein (BCRP), and OATP substrates using phenotypic probes.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive atorvastatin (ATV) 40 mg tablet on Day 1, followed by a washout period of 1 day, and then pravastatin (PRA) 40 mg + rosuvastatin (ROS) 10 mg tablets on Day 3 in Treatment A, Period 1. In Treatment B, Period 2 participants will receive filgotinib 200 mg tablet once daily for 11 days, with ATV 40 mg on Day 12 and PRA 40 mg + ROS 10 mg tablets on Day 14. Period 1 and Period 2 will be separated by a washout period of 3 days.
Drug: Atorvastatin · Drug: Pravastatin · Drug: Rosuvastatin · Drug: Filgotinib
Participants will receive filgotinib 200 mg tablet once daily for 11 days, with ATV 40 mg on Day 6 and PRA 40 mg + ROS 10 mg tablets on Day 8 in Treatment B, Period 1. In Treatment A, Period 2 participants will receive ATV 40 mg tablet on Day 18, followed by a washout period of 1 day and PRA 40 mg + ROS 10 mg tablets on Day 20. Period 1 and Period 2 will be separated by a washout period of 6 days.
Drug: Atorvastatin · Drug: Pravastatin · Drug: Rosuvastatin · Drug: Filgotinib
Administered as single dose tablet orally.
Administered as single dose tablet orally.
Administered as single dose tablet orally.
Administered as tablet orally once daily for 11 days.
Also known as: GS-6034, GLPG0634, Jyseleca
Pharmacokinetic (PK) Parameter: AUClast of ATV, PRA, and ROS
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Time frame: AB (Days 1,3,12,14) and BA (Days 6,8,18,20): Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 postdose; AB (Days 1,12) and BA (Days 6,18): 5,10,36 hours post dose; AB (Days 3,14) and BA (Days 8,20): 72 hours postdose
PK Parameter: AUCinf of ATV, PRA, and ROS
AUCinf is defined as the concentration of drug extrapolated to infinite time.
Time frame: AB (Days 1,3,12,14) and BA (Days 6,8,18,20): Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 postdose; AB (Days 1,12) and BA (Days 6,18): 5,10,36 hours post dose; AB (Days 3,14) and BA (Days 8,20): 72 hours postdose
PK Parameter: Cmax of ATV, PRA, and ROS
Cmax is defined as the maximum observed concentration of drug.
Time frame: AB (Days 1,3,12,14) and BA (Days 6,8,18,20): Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 postdose; AB (Days 1,12) and BA (Days 6,18): 5,10,36 hours post dose; AB (Days 3,14) and BA (Days 8,20): 72 hours postdose
Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, which did not necessarily have a causal relationship with the treatment. AE was therefore any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug. TEAEs: AE with an onset date on or after the study drug start date and no later than 30 days after study drug stop date; or any AE leading to study drug discontinuation.
Time frame: Sequence AB: First dose up to 47 days, Sequence BA: First dose up to 50 days
Percentage of Participants With Severity Grade 3 or Above Treatment-Emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were graded using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 of Adverse Events and Laboratory abnormalities. Laboratory abnormalities were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Life-threatening), Grade 5 (Death). Percentage of participants with Grade 3 or higher treatment-emergent laboratory abnormalities were reported.
Time frame: Sequence AB: First dose up to 47 days, Sequence BA: First dose up to 50 days
Participants were enrolled at a study site in the United States. The first participant was screened on 04 November 2020. The last study visit occurred on 13 January 2021.
| Milestone | Sequence AB | Sequence BA |
|---|---|---|
| Started | 14 | 13 |
| Completed | 13 | 12 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Investigator's discretion | 1 | 0 |
| Milestone | Sequence AB | Sequence BA |
|---|---|---|
| Started | 13 | 12 |
| Completed | 13 | 12 |
| Not completed | 0 | 0 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
| h*ng/mL | Atorvastatin | Pravastatin + Rosuvastatin | Filgotinib + Atorvastatin | Filgotinib + Pravastatin + Rosuvastatin |
|---|---|---|---|---|
| ATV | 78.8 ± 39.10 | — | 70.2 ± 27.08 | — |
| PRA | — | 199.5 ± 115.64 | — | 232.5 ± 137.76 |
| ROS | — | 62.6 ± 29.03 | — | 89.3 ± 34.63 |
AUCinf is defined as the concentration of drug extrapolated to infinite time.
| h*ng/mL | Atorvastatin | Pravastatin + Rosuvastatin | Filgotinib + Atorvastatin | Filgotinib + Pravastatin + Rosuvastatin |
|---|---|---|---|---|
| ATV | 80.8 ± 39.76 | — | 71.8 ± 27.30 | — |
| PRA | — | 201.3 ± 116.38 | — | 234.8 ± 137.43 |
| ROS | — | 66.0 ± 29.53 | — | 92.3 ± 34.94 |
Cmax is defined as the maximum observed concentration of drug.
| ng/mL | Atorvastatin | Pravastatin + Rosuvastatin | Filgotinib + Atorvastatin | Filgotinib + Pravastatin + Rosuvastatin |
|---|---|---|---|---|
| ATV | 19.7 ± 13.50 | — | 15.0 ± 7.81 | — |
| PRA | — | 84.2 ± 56.60 | — | 99.2 ± 65.68 |
| ROS | — | 7.5 ± 4.17 | — | 12.3 ± 6.00 |
An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, which did not necessarily have a causal relationship with the treatment. AE was therefore any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug. TEAEs: AE with an onset date on or after the study drug start date and no later than 30 days after study drug stop date; or any AE leading to study drug discontinuation.
| percentage of participants | Atorvastatin | Pravastatin + Rosuvastatin | Filgotinib | Filgotinib + Atorvastatin | Filgotinib + Pravastatin + Rosuvastatin |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) | 19.2 | 24.0 | 65.4 | 7.7 | 11.5 |
Treatment-emergent laboratory abnormalities were graded using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 of Adverse Events and Laboratory abnormalities. Laboratory abnormalities were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Life-threatening), Grade 5 (Death). Percentage of participants with Grade 3 or higher treatment-emergent laboratory abnormalities were reported.
| percentage of participants | Atorvastatin | Pravastatin + Rosuvastatin | Filgotinib | Filgotinib + Atorvastatin | Filgotinib + Pravastatin + Rosuvastatin |
|---|---|---|---|---|---|
| Percentage of Participants With Severity Grade 3 or Above Treatment-Emergent Laboratory Abnormalities | 0 | 0 | 3.8 | 0 | 0 |
Collected over Adverse Events: Sequence AB: First dose up to 47 days, Sequence BA: First dose up to 50 days All Cause-Mortality: Sequence AB: From randomization up to 47 days, Sequence BA: From randomization up to 50 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorvastatin | 0/27 (0%) | 0/26 (0%) | 2/26 (7.7%) |
| Pravastatin + Rosuvastatin | 0/27 (0%) | 0/25 (0%) | 4/25 (16%) |
| Filgotinib | 0/27 (0%) | 0/26 (0%) | 13/26 (50%) |
| Filgotinib + Atorvastatin | 0/27 (0%) | 0/26 (0%) | 2/26 (7.7%) |
| Filgotinib + Pravastatin + Rosuvastatin | 0/27 (0%) | 0/26 (0%) | 0/26 (0%) |
| Event | Atorvastatin | Pravastatin + Rosuvastatin | Filgotinib | Filgotinib + Atorvastatin | Filgotinib + Pravastatin + Rosuvastatin |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/26 | 2/25 | 8/26 | 0/26 | 0/26 |
| NauseaGastrointestinal disorders | 0/26 | 1/25 | 3/26 | 1/26 | 0/26 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/26 | 2/25 | 1/26 | 0/26 | 0/26 |
| ConstipationGastrointestinal disorders | 0/26 | 0/25 | 2/26 | 1/26 | 0/26 |
| MetrorrhagiaReproductive system and breast disorders | 0/26 | 0/25 | 2/26 | 0/26 | 0/26 |
The Safety Analysis Set included all randomized participants who received at least 1 dose of any study drug.
| Age, Continuous(years) | Sequence AB | Sequence BA | Total |
|---|---|---|---|
| Mean | 31 ± 7.2 | 29 ± 7.6 | 30 ± 7.3 |
| Sex: Female, Male(Participants) | Sequence AB | Sequence BA | Total |
|---|---|---|---|
| Female | 14 | 12 | 26 |
| Male | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Sequence AB | Sequence BA | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 14 | 12 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence AB | Sequence BA | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 |
| White | 10 | 9 | 19 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Nov 2020 to primary completion in Jan 2021, 2 months.
Results were first posted in Jan 2022, 1 year after primary completion.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 2 months is below that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634